Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lycia Therapeutics, Inc.

NASDAQ: LYCA · Life Sciences · 4 alerts · CIK 1806540

Share price
$28.61Close, Nov 16
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lycia Therapeutics, Inc. filings on SEC EDGAR ↗

5:13 PM ET Form 4
Insider Buying

Lycia Therapeutics 10% Owner Venrock Healthcare Capital Partners III L.P. Buys $224K of Stock

Venrock Healthcare Capital Partners III L.P., 10% Owner, bought 8,305 shares of Lycia Therapeutics, Inc. at $26.95 a share, worth $224K in total on Nov 2, 2026. Shares held after the trade: 6,858,542 (+0.1%).

Value
$224K
Shares
8,305
Price
$26.95
Role
10% Owner
Holding change
+0.1%
Trade date
Nov 2, 2026
7:25 PM ET Form 4
Insider Buying

Lycia Therapeutics 10% Owner Venrock Healthcare Capital Partners III L.P. Buys $639K of Stock

Venrock Healthcare Capital Partners III L.P., 10% Owner, bought 24,804 shares of Lycia Therapeutics, Inc. at $25.23 to $26.33 a share (average $25.78) in 4 transactions, worth $639K in total between Oct 28, 2026 and Oct 30, 2026. Shares held after the trade: 6,850,037 (+0.1%).

Value
$639K
Shares
24,804
Average price
$25.78
Role
10% Owner
Holding change
+0.1%
Trade date
Oct 28, 2026 to Oct 30, 2026
6:38 PM ET Form 4
Insider Buying

Lycia Therapeutics 10% Owner Venrock Healthcare Capital Partners III L.P. Buys $37.7M of Stock

Venrock Healthcare Capital Partners III L.P., 10% Owner, bought 2,045,440 shares of Lycia Therapeutics, Inc. at $18.00 to $26.97 a share (average $18.41) in 6 transactions, worth $37.7M in total between Oct 23, 2026 and Oct 27, 2026. Shares held after the trade: 6,825,233 (+0.5%).

Value
$37.7M
Shares
2,045,440
Average price
$18.41
Role
10% Owner
Holding change
+0.5%
Trade date
Oct 23, 2026 to Oct 27, 2026
4:55 PM ET 8-K
Capital Raise

Lycia Therapeutics Capital Raise

Lycia Therapeutics, Inc. filed its Amended and Restated Certificate of Incorporation and Bylaws in connection with the closing of its initial public offering. These governance changes were previously approved by the board and stockholders to take effect upon the IPO's completion.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.